Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,450 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Safety in Healthy Adults Clear all

Conditions: Phenylketonuria, Healthy
Interventions: SYNB1618, Placebo; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more

Conditions: Rabies, Rabies Immunisation
Interventions: ChAd155-RG, Placebo, Rabies Vaccine; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Healthy Participants, Dyslipidemia
Interventions: AZD4954, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more

Conditions: Avian Influenza
Interventions: aH5N1c, Placebo; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 3,196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 26
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more

Conditions: Healthy Adult Subjects
Interventions: ONO-7746; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)
Interventions: Psilocybin (drug), Dextromethorphan (DXM); Drug
Lead sponsor: Jennifer Mitchell; Other
Eligibility: 50 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Infections, Respiratory Tract
Interventions: GSK2140944, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diarrhea Infectious
Interventions: VENBETA6890, Placebo; Drug
Lead sponsor: Mark Klempner; Other
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Venezuelan Equine Encephalitis Virus Infection
Interventions: Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate, 0.9% saline placebo; Biological · Other
Lead sponsor: Ichor Medical Systems Incorporated; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Infection
Interventions: Cefazolin 2g for Injection USP and Dextrose Injection USP, Cefazolin 1.5g; Drug
Lead sponsor: B. Braun Medical Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers, Pharmacokinetics of ASP1941
Interventions: ASP1941, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV-F Particle Vaccine, Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A, Orthomyxovirdae, H5N1 Virus
Interventions: VRC-AVIDNA036-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Adult
Interventions: BMS-986142, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Anthrax, Anthrax Immunisation
Interventions: AV7909; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Covid19
Interventions: VXA-CoV2-1; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: Y-2 Sublingual Tablet, Placebo; Drug
Lead sponsor: Simcere Pharmaceutical Co., Ltd; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Glendale, California

Conditions: Muscular Dystrophies
Interventions: GSK3439171A, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteer
Interventions: Nacresertib, Placebo for Nacresertib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Anaheim, California

Conditions: HIV Infections
Interventions: VRC-HIVDNA016-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 44 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: GARDASIL®9 (G9), V540B; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Anaheim, California • Hallandale, Florida • Hollywood, Florida + 1 more

Conditions: Healthy Volunteer
Interventions: Bretisilocin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: Tuberculosis
Interventions: PNU-100480, Placebo; Drug
Lead sponsor: Sequella, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Participants
Interventions: LY03015 (LPM3770164 extended-release tablets); Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Search by objective public record fields.

Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

ONO-7746 Study in Healthy Adult Subject

A Study of Psychedelics in Healthy Older Adults With Low Well-being

A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers

Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA

Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers

Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults

Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects

Anthrax AV7909 Liquid vs Lyophilized

Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects

A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects

First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect

A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants

Candidate HIV Vaccine

Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).

A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants

Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults

A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects